Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine & its 15 metabolites by LC-MS

Bioanalysis

Volumn 3, Issue 7, 2011, Pages 745-761

  Rangiah, Kannan ^a   Hwang, Wei Ting ^a   Mesaros, Clementina ^a   Vachani, Anil ^a   Blair, Ian A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 4 (3 PYRIDYL)BUTANOIC ACID; BETA GLUCURONIDASE; BIOLOGICAL MARKER; COTININE; COTININE N OXIDE; GLUCURONIDE; NICOTINE; NICOTINE DERIVATIVE; NICOTINE N OXIDE; NORCOTININE; NORNICOTINE; TRANS 3' HYDROXYCOTININE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; HUMAN; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITE; PHENOTYPE; QUANTITATIVE ANALYSIS; SMOKING; URINALYSIS; URINE LEVEL;

BIOLOGICAL MARKERS; BIOPHARMACEUTICS; CHROMATOGRAPHY, LIQUID; FEMALE; GLUCURONIDES; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; NICOTINE; PHENOTYPE; SMOKING;

EID: 79953669940     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.42     Document Type: Article

References (75)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 291(10), 1238-1245 (2004). (Pubitemid 38541668)
2. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue. A tribute to Ernst L. Wynder. Chem. Res. Toxicol. 14(7), 767-790 (2001).
3. Hecht SS. Progress and challenges in selected areas of tobacco carcinogenesis. Chem. Res. Toxicol. 21(1), 160-171 (2008). (Pubitemid 351219717)
4. Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin. Cancer Biol. 14(6), 473-486 (2004). (Pubitemid 39360995)
5. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine. Tob. Res. 9(4), 511-518 (2007). (Pubitemid 46534464)
6. Kandel DB, Hu MC, Schaffran C, Udry JR, Benowitz NL. Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am. J. Epidemiol. 165(8), 901-910 (2007). (Pubitemid 46536667)
7. Shopland DR. Tobacco use and its contribution to early cancer mortality with a special emphasis on cigarette smoking. Environ. Health Perspect. 103 (Suppl. 8), 131-142 (1995). (Pubitemid 26040889)
8. Bach PB, Kattan MW, Thornquist MD et al. Variations in lung cancer risk among smokers. J. Natl. Cancer Inst. 95(6), 470-478 (2003). (Pubitemid 36432421)
9. van Zandwijk N. Chemoprevention of lung cancer. Lung Cancer 34 (Suppl. 3), S91-S94 (2001).
10. Lerman C, Jepson C, Wileyto EP et al. Genetic variation in nicotine metabolism predicts the effcacy of extended-duration transdermal nicotine therapy. Clin. Pharmacol. Ther. 87(5), 553-557 (2010).
11. Pastorino U. Lung cancer screening. Br. J. Cancer 102(12), 1681-1686 (2010).
12. Gorrod JW, Hibberd AR. The metabolism of nicotine-delta 1́ (5́)-iminium ion, in vivo and in vitro. Eur. J. Drug Metab Pharmacokinet. 7(4), 293-298 (1982). (Pubitemid 13185235)
13. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol. Rev. 57(1), 79-115 (2005). (Pubitemid 40283970)
14. Nakajima M, Yamamoto T, Nunoya K et al. Characterization of CYP2A6 involved in 3́-hydroxylation of cotinine in human liver microsomes. J. Pharmacol. Exp. Ther. 277(2), 1010-1015 (1996).
15. Johnstone E, Benowitz N, Cargill A et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin. Pharmacol. Ther. 80(4), 319-330 (2006). (Pubitemid 44479751)
16. Brown KM, von Weymarn LB, Murphy SE. Identifcation of N-(hydroxymethyl) norcotinine as a major product of cytochrome P450 2A6, but not cytochrome P450 2A13-catalyzed cotinine metabolism. Chem. Res. Toxicol. 18(12), 1792-1798 (2005). (Pubitemid 43023037)
17. Berg JZ, von Weymarn LB, Thompson EA et al. UGT2B10 genotype infuences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiol. Biomarkers Prev. 19(6), 1423-1431 (2010).
18. Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE. Nicotine metabolism in African-Americans and European-Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J. Pharmacol. Exp. Ther. 332(1), 202-209 (2010).
19. Chen G, Giambrone NE, Dluzen DF et al. Glucuronidation Genotypes and Nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res. 70(19), 7543-7552 (2010).
20. Nakajima M, Yokoi T Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation. Drug Metab. Pharmacokinet. 20(4), 227-235 (2005).
21. Lessov-Schlaggar CN, Benowitz NL, Jacob P, Swan GE. Genetic infuences on individual differences in nicotine glucuronidation. Twin. Res. Hum. Genet. 12(5), 507-513 (2009).
22. Hecht SS, Hatsukami DK, Bonilla LE, Hochalter JB. Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl) butanoic acid in human urine: a substantial pathway of nicotine metabolism. Chem. Res. Toxicol. 12(2), 172-179 (1999). (Pubitemid 29096065)
23. Park SB, Jacob P 3rd, Benowitz NL, Cashman JR. Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1́-oxide. Chem. Res. Toxicol. 6(6), 880-888 (1993). (Pubitemid 23351213)
24. Murphy SE, Johnson LM, Pullo DA. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chem. Res. Toxicol. 12(7), 639-645 (1999). (Pubitemid 29354747)
25. Di YM, Chow VD, Yang LP, Zhou SF. Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Curr. Drug Metab. 10(7), 754-780 (2009).
26. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43,149-173 (2003). (Pubitemid 37372638)
27. Smith BD, Sanders JL, Porubsky PR, Lushington GH, Stout CD, Scott EE. Structure of the human lung cytochrome P450 2A13. J. Biol. Chem. 282(23), 17306-17313 (2007). (Pubitemid 47093207)
28. Bao Z, He XY, Ding X, Prabhu S, Hong JY. Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos. 33(2), 258-261 (2005). (Pubitemid 40216593)
29. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental infuences on the ratio of 3́hydroxycotinine to cotinine in plasma and urine. Pharmacogenet. Genomics 19(5), 388-398 (2009).
30. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37,269-296 (1997). (Pubitemid 27238877)
31. Hecht SS. Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23(6), 907-922 (2002). (Pubitemid 34752946)
32. Ciccimaro E, Blair IA. Stable-isotope dilution LC-MS for quantitative biomarker ana lysis. Bioana lysis 2(2), 311-341 (2010).
33. Tuomi T, Johnsson T, Reijula K. Analysis of nicotine, 3-hydroxycotinine, cotinine and caffeine in urine of passive smokers by HPLC-tandem mass spectrometry. Clin. Chem. 45(12), 2164-2172 (1999).
34. Moyer TP, Charlson JR, Enger RJ et al. Simultaneous ana lysis of nicotine, nicotine metabolites and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profles. Clin. Chem. 48(9), 1460-1471 (2002). (Pubitemid 34925782)
35. Xu X, Iba MM, Weisel CP. Simultaneous and sensitive measurement of anabasine, nicotine and nicotine metabolites in human urine by liquid chromatography-tandem mass spectrometry. Clin. Chem. 50(12), 2323-2330 (2004). (Pubitemid 39552168)
36. Heavner DL, Richardson JD, Morgan WT, Ogden MW. Validation and application of a method for the determination of nicotine and fve major metabolites in smokers' urine by solid-phase extraction and liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 19(4), 312-328 (2005). (Pubitemid 40872658)
37. Hoofnagle AN, Laha TJ, Rainey PM, Sadrzadeh SM. Specifc detection of anabasine, nicotine, and nicotine metabolites in urine by liquid chromatography-tandem mass spectrometry. Am. J. Clin. Pathol. 126(6), 880-887 (2006). (Pubitemid 44901840)
38. Kataoka H, Inoue R, Yagi K, Saito K. Determination of nicotine, cotinine and related alkaloids in human urine and saliva by automated in-tube solid-phase microextraction coupled with liquid chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 49(1), 108-114 (2009).
39. Miller EI, Norris HR, Rollins DE, Tiffany ST, Wilkins DG. A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometry. J. Chromatogr. B 878(9-10), 725-737 (2010).
40. Upadhyaya P, Kenney PM, Hochalter JB, Wang M, Hecht SS. Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse. Carcinogenesis 20(8), 1577-1582 (1999). (Pubitemid 29385448)
41. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS. J. 9(1), E109-E114 (2007).
42. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
43. Forgy EW. cluster analysis of multivariate data-effciency vs interpretability of classifcations. Biometrics 21(3), 768-& (1965).
44. Everitt BS, Landau S, Leese M Stahl D. Cluster Ana lysis (Wiley Series in Probability and Statistics) 5th Edition. Chapter 5. John Wiley and Sons, Chichester, UK (2011).
45. Feyerabend C, Russell MAH. Effect of urinary pH and nicotine excretion rate on plasma nicotine during cigarette-smoking and chewing nicotine gum. Br. J. Clin. Pharmacol. 5(4), 293-297 (1978). (Pubitemid 8297730)
46. Matsukura S, Sakamoto N, Takahashi K, Matsuyama H, Muranaka H. Effect of pH and urine fow on urinary nicotine excretion after smoking cigarettes. Clin. Pharmacol. Ther. 25(5), 549-554 (1979). (Pubitemid 9208911)
47. Benowitz NL, Jacob P. Nicotine renal excretion rate infuences nicotine intake during cigarette-smoking. J. Pharmacol. Exp. Ther. 234(1), 153-155 (1985). (Pubitemid 15034904)
48. Benowitz NL, Lessov-Schlaggar CN, Swan GE. Genetic infuences in the variation in renal clearance of nicotine and cotinine. Clin. Pharmacol. Ther. 84(2), 243-247 (2008).
49. Benowitz NL, Jacob P, Fong I, Gupta S. Nicotine metabolic profle in man-comparison of cigarette-smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268(1), 296-303 (1994). (Pubitemid 24039102)
50. Feng S, Kapur S, Sarkar M, Muhammad R, Mendes P, Roethig HJ. The relationship between nicotine retention and urinary excretion of nicotine and its fve major metabolites in adult male smokers. Clin. Pharmacol. Ther. 8,S42-S43 (2007).
51. Yamanaka H, Nakajima M, Nishimura K et al. Metabolic profle of nicotine in subjects whose CYP2A6 gene is deleted. Eur. J. Pharm. Sci. 22(5), 419-425 (2004). (Pubitemid 38953900)
52. Nakajima M, Fukami T, Yamanaka H et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther. 80(3), 282-297 (2006). (Pubitemid 44313906)
53. Liang Q, Roethig HJ, Lipowicz PJ, Jin Y, Mendes PE. The effect of cigarette burn time on exposure to nicotine and carbon monoxide in adult smokers. Regul. Toxicol. Pharmacol. 50(1), 66-74 (2008). (Pubitemid 350298161)
54. Mendes P, Liang QW, Frost-Pineda K, Munjal S, Walk RA, Roethig HJ. The relationship between smoking machine derived tar yields and biomarkers of exposure in adult cigarette smokers in the US. Regul. Toxicol. Pharmacol. 55(1), 17-27 (2009).
55. Roethig HJ, Munjal S, Feng SX et al. Population estimates for biomarkers of exposure to cigarette smoke in adult US cigarette smokers. Nicotine. Tob. Res. 11(10), 1216-1225 (2009).
56. Derby KS, Cuthrell K, Caberto C et al. Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer. Int. J. Cancer 125(10), 2418-2424 (2009).
57. Berg JZ, von Weymarn LB, Thompson EA et al. UGT2B10 genotype infuences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiol. Biomarkers Prevent. 19(6), 1423-1431 (2010).
58. Wang JZ, Roethig HJ, Appleton S, Werley M, Muhammad-Kah R, Mendes P. The effect of menthol containing cigarettes on adult smokers' exposure to nicotine and carbon monoxide. Regul. Toxicol. Pharmacol. 57(1), 24-30 (2010).
59. Fan Z, Xie FW, Xia QL, Wang S, Ding L, Liu HM. Simultaneous determination of nicotine and its nine metabolites in human urine by LC-MS-MS. Chromatographia 68(7-8), 623-627 (2008).
60. Derby KS, Cuthrell K, Caberto C et al. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol. Biomarkers Prev. 17(12), 3526-3535 (2008).
61. Mooney ME, Li ZZ, Murphy SE, Pentel PR, Le C, Hatsukami DK. Stability of the nicotine metabolite ratio in ad libitum and reducing smokers. Cancer Epidemiol. Biomarkers Prev. 17(6), 1396-1400 (2008).
62. Ho MK, Mwenifumbo JC, Al KN et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin. Pharmacol. Ther. 85(6), 635-643 (2009).
63. Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. Pediatrics 122(3), e643-e647 (2008).
64. Levi M, Dempsey DA, Benowitz NL, Sheiner LB. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. J. Pharmacokinet. Pharmacodyn. 34(1), 23-34 (2007). (Pubitemid 46122546)
65. Schwartz SL, McKennis H Jr. Studies on the degradation of the pyrrolidine ring of (-)-nicotine in vivo. Formation of γ-(3-pyridyl)-γ- oxobutyric acid. J. Biol. Chem. 238), 1807-1812 (1963).
66. Hecht SS, Hochalter JB, Villalta PW, Murphy SE. 2́-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc Natl Acad. Sci. USA. 97(23), 12493-12497 (2000).
67. Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol. Biochem. Behav. 92(1), 6-11 (2009).
68. Dempsey D, Tutka P, Jacob P 3rd et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76(1), 64-72 (2004). (Pubitemid 38844735)
69. Church TR, Anderson KE, Le C et al. Temporal stability of urinary and plasma biomarkers of tobacco smoke exposure among cigarette smokers. Biomarkers 15(4), 345-352 (2010).
70. Penning TM, Lerman C Genomics of smoking exposure and cessation: lessons for cancer prevention and treatment. Cancer Prev. Res. (Phila Pa) 1(2), 80-83 (2008).
71. Alfano CM, Klesges RC, Murray DM et al. Physical activity in relation to all-site and lung cancer incidence and mortality in current and former smokers. Cancer Epidemiol. Biomarkers Prev. 13(12), 2233-2241 (2004). (Pubitemid 40054322)
72. Kubik A, Zatloukal P, Tomasek L, Pauk N, Petruzelka L, Plesko I. Lung cancer risk among nonsmoking women in relation to diet and physical activity. Neoplasma 51(2), 136-143 (2004). (Pubitemid 38596145)
73. Buchner FL, Bueno-de-Mesquita HB, Ros MM et al. Variety in fruit and vegetable consumption and the risk of lung cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol. Biomarkers Prev. 19(9), 2278-2286 (2010).
74. Fant RV, Buchhalter AR, Buchman AC, Henningfeld JE. Pharmacotherapy for tobacco dependence. Handb. Exp. Pharmacol. (192), 487-510 (2009).
75. Marquez-Garban DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. Ann. N. Y. Acad. Sci. 1155), 194-205 (2009).